---
title: "Modeling Manual"
date: "2026-02-22"
description: "Comprehensive guide to pharmacometric modeling including PK/PD models, time-to-event analysis, goodness-of-fit assessment, and model building best practices."
---

::: {.callout-caution title="Under construction"}
:::

> Model-based analysis is more an art than a science. -Lewis B. Sheiner, MD

Hands-on guides to pharmacometric model building â€” tool-agnostic, with an emphasis on R and NONMEM.

::: {.grid}

::: {.g-col-12 .g-col-md-6 .index-card}
[PK Models](pk/pk/index.qmd){.card-title}
Structural models for drug concentration-time profiles.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[PD Models](pd/pd/index.qmd){.card-title}
Models linking drug concentrations to pharmacological effects.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[PKPD / E-R](pkpd/pkpd/index.qmd){.card-title}
Integrated exposure-response models connecting PK and PD.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Time-to-event](tte/tte/index.qmd){.card-title}
Survival analysis and event-rate modeling.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[C-QTc](qt/index.qmd){.card-title}
Cardiac safety modeling for QT interval prolongation.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Goodness-of-fit](gof/gof-cts/index.qmd){.card-title}
Diagnostic tools for evaluating model performance.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Priors](priors/index.qmd){.card-title}
Bayesian prior specification for population models.
:::

::: {.g-col-12 .g-col-md-6 .index-card}
[Variability](variability/index.qmd){.card-title}
Between-subject and residual variability in population models.
:::

:::

## Important considerations

### Impact of a model [@musuambaScientificRegulatoryEvaluation2021; @skottheimrustenScientificRegulatoryEvaluation2021]

* What is the modeling used for? (e.g., bridging, dose, SmPC^[Summary of Product Characteristics] parameters?)
  * Does the conclusion align with the aim?
* What data is available?
  * Rich data
  * Sparse data
* What is the structural model?
  * Reasonable parameter estimates and RSE^[Relative standard error]'s?
  * Graphical evaluation (VPC^[Visual Predictive Check] first)
  * Covariate evaluation

* Exposure-response is generally non-informative if only one dose-level is given, even if weight-adjusted

### Reviewing models
* Does my conclusion align with the authors?
* Questions NGN (eNGiNe)
  * Need-to-know: Will affect conclusion (Major objection)
  * Good-to-know: Could affect conclusion (Other concern)
  * Nice-to-know: Won't affect conclusion (avoid asking this question)

## Terminology

**Parsimony:** The idea is that comparing two models, the model with fewer parameters is preferable, given that all else is equal.

**Shrinkage:** Shrinkage quantifies how much individual estimates regress towards the population mean under the given sampling schedule [@savicImportanceShrinkageEmpirical2009].
It also measures the amount of information on a parameter in the current data used to estimate it.

**Robustness:** Robustness describes a model's ability to perform reliably under varying assumptions or when faced with unusual or extreme data points.
Robust models produce stable parameter estimates even if underlying assumptions (normality, independence, linearity, etc.) are not perfectly met.
Non-robust models may yield misleading results or parameter instability if assumptions are violated.

**Misspecification:** Misspecification occurs when a model's mathematical structure or assumptions differ significantly from the underlying data-generating process.

::: {.callout-note}
It is reasonable to assume that there will always be *some* model misspecification.
We recall:

> All models are wrong, but some are useful. -George E. P. Box, PhD

:::

**Overfitting:** The model fits training data so well that it fails on new data (poor generalization).

**Identifiability:** Whether parameters can be uniquely estimated from the data.
Lack of identifiability means multiple parameter combinations yield the same likelihood.

**Bias-variance tradeoff:** Balancing a model's simplicity (high bias, low variance) versus complexity (low bias, high variance) to optimize predictive accuracy.

## References

::: {#refs}
:::
